GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Days Sales Outstanding

ANIK (Anika Therapeutics) Days Sales Outstanding : 73.15 (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Days Sales Outstanding?

Anika Therapeutics's average Accounts Receivable for the three months ended in Sep. 2024 was $31.1 Mil. Anika Therapeutics's Revenue for the three months ended in Sep. 2024 was $38.8 Mil. Hence, Anika Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2024 was 73.15.

The historical rank and industry rank for Anika Therapeutics's Days Sales Outstanding or its related term are showing as below:

ANIK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.03   Med: 75.73   Max: 86.94
Current: 73.3

During the past 13 years, Anika Therapeutics's highest Days Sales Outstanding was 86.94. The lowest was 62.03. And the median was 75.73.

ANIK's Days Sales Outstanding is ranked worse than
51.24% of 970 companies
in the Drug Manufacturers industry
Industry Median: 71.605 vs ANIK: 73.30

Anika Therapeutics's Days Sales Outstanding declined from Sep. 2023 (78.58) to Sep. 2024 (73.15).


Anika Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Anika Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Days Sales Outstanding Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.83 66.00 66.61 75.31 77.30

Anika Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.58 75.01 76.60 71.67 73.15

Competitive Comparison of Anika Therapeutics's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Days Sales Outstanding falls into.



Anika Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Anika Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (34.627 + 35.961) / 2 ) / 166.662*365
=35.294 / 166.662*365
=77.30

Anika Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding (Q: Sep. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2024 ) + Accounts Receivable (A: Sep. 2024 )) / count ) / Revenue (A: Sep. 2024 )*Days in Period
=( (33.773 + 28.357) / 2 ) / 38.753*365 / 4
=31.065 / 38.753*365 / 4
=73.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anika Therapeutics  (NAS:ANIK) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Anika Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767